2seventy bio, Inc. (TSVT) Stock Price, News, Quote & History
WEBFind the latest 2seventy bio, Inc. (TSVT) stock quote, history, news and other vital information to help you with your stock trading and investing.
2seventy bio, Inc. (TSVT) Latest Stock News & Headlines - Yahoo …
WEBGet the latest 2seventy bio, Inc. (TSVT) stock news and headlines to help you in your trading and investing decisions.
2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up
WEBJan 31, 2024 · 2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.
TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study
WEB4 days ago · TSVT anticipates that the discontinuation of the late-stage study will save more than $80 million in near-term expenditures and accelerate its path to breakeven in 2025.
2seventy bio, Inc. (TSVT) Latest Press Releases & Corporate News ...
WEBGet the latest 2seventy bio, Inc. (TSVT) stock news and headlines to help you in your trading and investing decisions.
2seventy bio, Inc. (TSVT) stock price, news, quote and history
WEBFind the latest 2seventy bio, Inc. (TSVT) stock quote, history, news and other vital information to help you with your stock trading and investing.
2seventy bio Inc (TSVT) Reports Mixed Financial Results Amid …
WEBMar 5, 2024 · 2seventy bio Inc (NASDAQ:TSVT) is at a pivotal point, with the potential expansion of Abecma's label and the strategic asset sale to Regeneron. The company's focus on operational efficiency and ...
Bristol Myers (BMY), TSVT CAR T-Cell Therapy to Face FDA's ODAC
WEBFeb 6, 2024 · Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.
When Will 2seventy bio, Inc. (NASDAQ:TSVT) Turn A Profit?
WEBMar 6, 2024 · With the business potentially at an important milestone, we thought we'd take a closer look at 2seventy bio, Inc.'s (NASDAQ:TSVT) future prospects. 2seventy bio, Inc., a cell and gene therapy ...
Bristol Myers (BMY), TSVT Cell Therapy Abecma Faces Setback
WEBNov 21, 2023 · BMY and TSVT are jointly developing and commercializing Abecma in the United States. Both companies anticipate that the committee will review data related to the secondary endpoint of overall ...